Figure 4 | Scientific Reports

Figure 4

From: A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants

Figure 4

Immune monitoring of recipients post Alemtuzumab induction and Treg infusion. Absolute cell numbers (symbols) and grand median (- line) of T, B, and NK, Tregs per uL of blood from pre-transplant to 12 months post-transplant in all nine recipients (n = 9). Note: Alemtuzumab was given on day 0 and 2 of transplant, and Tregs were infused at two months post-transplant.

Back to article page